These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 30238583)

  • 21. Topical application of a vitamin D analogue exacerbates atopic dermatitis and induces the atopic dermatitis-like phenotype in Stat6VT mice.
    Turner MJ; Dasilva-Arnold SC; Yi Q; Mehrotra P; Kaplan MH; Travers JB
    Pediatr Dermatol; 2013; 30(5):574-8. PubMed ID: 23889122
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study.
    Schwensen JF; Clemmensen A; Sand C; Gniadecki R; Skov L; Zachariae C; Iversen L; Rasmussen M; Thomsen SF
    Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28906051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE).
    Thaçi D; Humeniuk J; Frambach Y; Bissonnette R; Goodman JJ; Shevade S; Gong Y; Papavassilis C;
    Br J Dermatol; 2015 Sep; 173(3):777-87. PubMed ID: 25823958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pseudoleucoderma after injections of afamelanotide in a patient with atopic dermatitis.
    von Bartenwerffer W; Siebenhaar G; Hunzelmann N
    Acta Derm Venereol; 2011 Sep; 91(5):578-9. PubMed ID: 21597671
    [No Abstract]   [Full Text] [Related]  

  • 25. Dermatitis during efalizumab treatment in a patient with psoriasis vulgaris.
    de Groot M; de Rie MA; Bos JD
    Br J Dermatol; 2005 Oct; 153(4):843-4. PubMed ID: 16181475
    [No Abstract]   [Full Text] [Related]  

  • 26. Dupilumab (Dupixent) for moderate to severe atopic dermatitis.
    Med Lett Drugs Ther; 2017 Apr; 59(1519):64-66. PubMed ID: 28419072
    [No Abstract]   [Full Text] [Related]  

  • 27. Ruxolitinib (Opzelura) for atopic dermatitis.
    Med Lett Drugs Ther; 2022 Jan; 64(1642):12-13. PubMed ID: 35134043
    [No Abstract]   [Full Text] [Related]  

  • 28. The beginning of biological treatment era in the atopic dermatitis management.
    D'erme AM
    Dermatol Ther; 2016 May; 29(3):208-9. PubMed ID: 26331894
    [No Abstract]   [Full Text] [Related]  

  • 29. Monoclonal Antibodies for Atopic Dermatitis: Progress and Potential.
    Vakharia PP; Silverberg JI
    BioDrugs; 2017 Oct; 31(5):409-422. PubMed ID: 28853008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of and factors influencing sensitization to corticosteroids in a Danish patch test population.
    Vind-Kezunovic D; Johansen JD; Carlsen BC
    Contact Dermatitis; 2011 Jun; 64(6):325-9. PubMed ID: 21457277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Atopic eczema. Update of the therapeutic options].
    Abeck D
    MMW Fortschr Med; 2011 Apr; 153(16):51-3. PubMed ID: 22329325
    [No Abstract]   [Full Text] [Related]  

  • 32. Secukinumab for psoriasis in a patient with hepatitis B.
    Feaster B; Cline A; Feldman SR
    Dermatol Online J; 2018 Sep; 24(9):. PubMed ID: 30677838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Secukinumab: a review in moderate to severe plaque psoriasis.
    Garnock-Jones KP
    Am J Clin Dermatol; 2015 Aug; 16(4):323-330. PubMed ID: 26202871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Occlusion therapy in inflammatory cutaneous diseases.
    Kansal NK; Upadhyaya A
    Dermatol Ther; 2018 Nov; 31(6):e12712. PubMed ID: 30253005
    [No Abstract]   [Full Text] [Related]  

  • 35. Ustekinumab (Stelara) for psoriasis.
    Med Lett Drugs Ther; 2010 Jan; 52(1330):7-8. PubMed ID: 20208473
    [No Abstract]   [Full Text] [Related]  

  • 36. Non-psoriatic dermatologic uses of monoclonal antibody therapy.
    Sockolov ME; Alikhan A; Zargari O
    J Dermatolog Treat; 2009; 20(6):319-27. PubMed ID: 19954387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New alcohol flushing in a patient with atopic dermatitis under therapy with dupilumab.
    Herz S; Petri M; Sondermann W
    Dermatol Ther; 2019 Jan; 32(1):e12762. PubMed ID: 30288874
    [No Abstract]   [Full Text] [Related]  

  • 38. Autoimmune hepatitis in two psoriasis patients treated with inflixmab.
    Goujon C; Dahel K; Bérard F; Guillot I; Gunera-Saad N; Nicolas JF
    J Am Acad Dermatol; 2010 Aug; 63(2):e43-4. PubMed ID: 20633783
    [No Abstract]   [Full Text] [Related]  

  • 39. Long-term remission induced by secukinumab in a 13-year-old boy having recalcitrant chronic erythrodermic psoriasis.
    Dogra S; Bishnoi A; Narang T; Handa S
    Dermatol Ther; 2018 Jul; 31(4):e12611. PubMed ID: 29687662
    [No Abstract]   [Full Text] [Related]  

  • 40. Efalizumab-induced lupus-like syndrome.
    Durox H; Sparsa A; Loustaud-Ratti V; Prey S; Gondran G; Manea P; Vidal E; Bedane C
    Acta Derm Venereol; 2008; 88(3):270-1. PubMed ID: 18480928
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.